On Wednesday, Metsera got a positive adjustment to its Relative Strength (RS) Rating, from 64 to 71.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks often have an RS Rating north of 80 as they launch their largest climbs. See if Metsera can continue to rebound and hit that benchmark.
Metsera is not currently showing a potential entry point. See if the stock goes on to form a chart pattern that could launch a new move.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 0%.
Metsera holds the No. 232 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
